1.46
0.00 (0.00%)
| Penutupan Terdahulu | 1.46 |
| Buka | 1.47 |
| Jumlah Dagangan | 402,302 |
| Purata Dagangan (3B) | 912,534 |
| Modal Pasaran | 158,090,272 |
| Harga / Jualan (P/S) | 7.30 |
| Harga / Buku (P/B) | 1.08 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2025 |
| Margin Operasi (TTM) | -1,222.27% |
| EPS Cair (TTM) | -1.59 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -39.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.72% |
| Nisbah Semasa (MRQ) | 5.06 |
| Aliran Tunai Operasi (OCF TTM) | -12.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.41 M |
| Pulangan Atas Aset (ROA TTM) | -18.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -91.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | Aclaris Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 0.5 |
| Purata | 1.50 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.69% |
| % Dimiliki oleh Institusi | 88.24% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 16.00 (HC Wainwright & Co., 995.89%) | Beli |
| Median | 8.50 (482.19%) | |
| Rendah | 6.00 (Piper Sandler, 310.96%) | Beli |
| Purata | 9.75 (567.81%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 1.44 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 10 Jul 2025 | 6.00 (310.96%) | Beli | 1.44 |
| HC Wainwright & Co. | 25 Jun 2025 | 16.00 (995.89%) | Beli | 1.63 |
| 14 May 2025 | 16.00 (995.89%) | Beli | 1.18 | |
| Wedbush | 28 May 2025 | 8.00 (447.95%) | Beli | 1.41 |
| Scotiabank | 09 May 2025 | 9.00 (516.44%) | Beli | 1.26 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |